Evidence Updates
Atrial Fibrillation Management: CHA2DS2-VASc in Clinical Practice
Atrial fibrillation affects over 50 million people globally and accounts for one in three ischemic strokes. Guideline-adherent anticoagulation — driven by CHA2DS2-VASc — reduces stroke risk by up to 64%. Real-world data confirm that adherent OAC significantly cuts mortality and stroke vs no treatment. Know the score. Treat the score.
TL;DR: AF affects over 50 million people globally and accounts for one in three ischemic strokes. Guideline-adherent anticoagulation — driven by CHA2DS2-VASc — reduces stroke risk by up to 64%. Real-world data confirm that adherent OAC significantly cuts mortality and stroke vs no treatment.
CHA2DS2-VASc in Practice
| Risk Factor | Points |
|---|---|
| CHF / LV dysfunction | 1 |
| Hypertension | 1 |
| Age ≥75 | 2 |
| Diabetes | 1 |
| Prior stroke/TIA | 2 |
| Vascular disease | 1 |
| Age 65–74 | 1 |
| Female sex | 1 |
Max: 9 points. Score ≥2 → OAC recommended.
NOACs vs Warfarin
Guidelines prefer NOACs for non-valvular AF. Warfarin remains indicated for mechanical prosthetic valves and moderate-severe rheumatic mitral stenosis.
Rate vs Rhythm Control
EAST-AFNET 4 (2020) showed early rhythm control within 1 year of AF diagnosis significantly reduced CV death, stroke, and worsening heart failure. Catheter ablation is now first-line for symptomatic paroxysmal AF.
Evidence: Real-World AF Management
Shantsila A et al. (2023) AF-GEN-UK Registry: guideline-adherent OAC associated with 52% reduction in 1-year mortality (aHR 0.48) and 89% reduction in stroke (aHR 0.11). Europace. 2023;25(2):308–317. PMID: 36037021.
References
- Shantsila A et al. Europace. 2023;25(2):308–317. PMID: 36037021.
- Gorczyca I et al. Cardiol J. 2023;30(4):646–653. PMID: 34671967.
- Hindricks G et al. Eur Heart J. 2021;42(5):373–498. PMID: 32860505.
- Kirchhof P et al. N Engl J Med. 2020;383(14):1305–1316. PMID: 32865375.